Interestingly, Hill et al. [66] evaluated patient-derived ovarian cancer organoids, and found that a functional defect in HR in the organoids correlated with PARP inhibitor sensitivity, whereas a functional defect in replication fork protection correlated more strongly with carboplatin sensitivity. The gene discussed is PARP1; the disease is ovarian carcinoma.